MAP2K7 and cancer: Currently, DCC-3116 is undergoing Phase 1/2 clinical trials (NCT04892017, NCT05957367) to evaluate its safety, tolerability, and preliminary efficacy as both a monotherapy and in combination with other cancer therapies, such as MEK and KRAS G12C inhibitors, in patients with advanced or metastatic solid tumors.